Boehringer Ingelheim has awarded Patheon with two projects valued at more than $18 million during a three-year period. The projects are both fixed-dose combination drugs in development for the treatment of type II diabetes.

Mark Kontny, Patheon’s president of Pharmaceutical Development Services and chief scientific officer said, “I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules. It is this kind of support and recognition that has enabled us to develop our market leading position in pharmaceutical development services.”